Prismic Pharmaceuticals is a US-based specialty pharmaceutical company dedicated to addressing the opioid crisis by developing novel non-addictive prescription drugs for the treatment of pain, inflammation, and neurological disorders, based on formulations utilizing the company’s micro-PEA development platform. Such formulations take advantage of micro-PEA’s “synergistic” or “entourage” effect on certain drugs impacting the endocannabinoid system. This means that lower doses of those drugs may be administered together with micro-PEA to achieve the desired therapeutic effect. This includes the potential combination or concomitant use of micro-PEA formulations with drugs such as THC, CBD, certain anticonvulsants, and opioids where studies have indicated opioid-sparing and tolerance delaying properties of micro-PEA which may impact the development of dependence in patients. 

The company’s first prescription drug candidate, PP-101, a 600 mg tablet of micro-PEA, is anticipated to commence a Phase 2/3 accelerated clinical development program in early 2020 as a concomitant medication to be administered with pregabalin (Pfizer’s Lyrica®) for the treatment of fibromyalgia. 

Prismic has exclusive worldwide licensing rights (except for Italy and Spain) to micro-PEA, a patent-protected form of palmitoylethanolamide with particle sizes of 0.6 – 10 microns, on which the company’s development platform is based and from which Prismic’s lead prescription drug candidate, PP-101, has been formulated. 

Micro-PEA is protected by an extensive portfolio of issued and pending US and international patents. 


FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) finalized the acquisition of Prismic Pharmaceuticals, Inc. on June 28, 2019.  Prismic is now a wholly owned subsidiary of FSD Pharma.  To view the press release ...


Prismic Pharmaceuticals